The European Atherosclerosis Society (EAS) and the American Heart Association (AHA) both agree that ApoB measurement may be considered reasonable for cardiovascular risk assessment, particularly in patients with metabolic syndrome, including individuals with obesity, diabetes mellitus, high triglycerides, and very low LDL-C levels [43,44]. This evidence concerns the gene APOB and diabetes mellitus.